Urodynamic Evaluation in India and UAE | Complete Patient Guide

• IDEAL CANDIDATES:

• Women with symptoms of stress, urgency, or mixed urinary incontinence who have failed 12 weeks of supervised conservative therapy (pelvic floor muscle training, bladder retraining) and are being considered for surgical intervention (mid-urethral sling, Burch colposuspension, or bulking agents)

• Men with lower urinary tract symptoms (LUTS) due to suspected benign prostatic obstruction (BPO) where pressure-flow studies will calculate BOOI and BCI to guide decision between TURP, laser enucleation [HoLEP/ThuLEP], or watchful waiting

• Patients with neurogenic bladder secondary to spinal cord injury, multiple sclerosis, Parkinson's disease, spina bifida, or diabetic autonomic neuropathy requiring risk stratification of upper urinary tract (UUT) status

• Children with refractory enuresis, recurrent UTIs, or suspected posterior urethral valves/vesico-ureteric reflux unresponsive to pharmacotherapy

• Patients with post-prostatectomy incontinence being evaluated for artificial urinary sphincter (AUS) or male sling placement

• Women with pelvic organ prolapse ≥ POP-Q Stage II undergoing pre-operative assessment for occult stress incontinence (Valsalva LPP < 60 cmH₂O threshold)

• Any patient with an elevated post-void residual (>150 mL on two separate occasions) of unclear aetiology

• REQUIRED PRE-PROCEDURE DIAGNOSTICS:

• Urinalysis and midstream urine culture (study must be postponed if active bacteriuria is confirmed; Nitrofurantoin 50 mg TDS × 5 days or Trimethoprim 200 mg OD × 7 days prescribed prophylactically in high-risk patients)

• Renal function panel (serum creatinine, eGFR) — mandatory if contrast-enhanced video-urodynamics planned

• Validated symptom questionnaires: ICIQ-UI SF, OAB-q, IIQ-7, or AUASI (depending on gender and clinical presentation)

• Bladder diary (minimum 3-day frequency-volume chart documenting voids, urgency episodes, and fluid intake)

• Pelvic ultrasound (post-void residual + upper tract screening for hydronephrosis)

• Cystoscopy if haematuria, suspected urethral stricture, or bladder lesion is present (usually performed at the same visit under local anaesthesia)

• Neurological assessment and MRI spine in suspected neurogenic cases

• CONTRAINDICATIONS / CAUTIONS:

• Active urinary tract infection (absolute contraindication — defer study until urine is sterile)

• Uncorrected coagulopathy or anticoagulation with INR >2.5 (relative; consider bridging protocol)

• Urethral or bladder trauma requiring acute surgical management

• Severe latex allergy (latex-free catheters must be confirmed in advance)

• Pregnancy (ionising radiation from video-urodynamics is contraindicated; non-radiological UDS may be performed with extreme caution)

• Patients with implanted cardiac devices (pacemakers, ICDs) require EMG electrode placement away from the device and cardiology clearance for patch-EMG configurations

Urodynamic Studies are not a single test but a modular diagnostic pathway. The specific components selected are tailored to the clinical question, patient phenotype, and degree of complexity.

1. UROFLOWMETRY + POST-VOID RESIDUAL (PVR)

The entry-level, non-invasive test. The patient voids into a calibrated flow meter (rotating disk or gravimetric), generating a flow-time curve. Key parameters: maximum flow rate (Qmax), average flow rate (Qave), voided volume, and flow time. A Qmax <10 mL/s with voided volume >150 mL is strongly suggestive of outflow obstruction or impaired detrusor contractility. PVR >150 mL on portable bladder scan or transabdominal ultrasound confirms incomplete emptying. This test takes 15–20 minutes and requires no catheterisation.

2. MULTICHANNEL FILLING CYSTOMETRY

A 6 Fr dual-lumen suprapubic or transurethral filling catheter instils room-temperature (or body-temperature) normal saline at a medium fill rate (50–100 mL/min for adults). Simultaneous Pves and Pabd are recorded; Pdet is computed in real time. The clinician documents: first sensation of filling (FSF), first desire to void (FDV), strong desire to void (SDV), cystometric capacity (CC), detrusor overactivity episodes, and compliance (ΔVolume/ΔPdet — normal >20 mL/cmH₂O; <10 mL/cmH₂O indicates dangerously low compliance placing the upper urinary tract at risk). Provocative manoeuvres (coughing, jumping, hand-washing) unmask stress or mixed incontinence.

3. PRESSURE-FLOW VOIDING STUDY

Following cystometry, the patient voids with catheters in situ. The simultaneous Pdet and Qmax plot is analysed using the ICS nomogram or the Schafer nomogram to classify the voiding pattern as obstructed, equivocal, or unobstructed, and to calculate the BCI and BOOI. This is the definitive investigation before any surgical intervention for LUTS/BPO.

4. URETHRAL PRESSURE PROFILOMETRY (UPP) AND ABDOMINAL LEAK POINT PRESSURE (ALPP / VLPP)

UPP withdraws the catheter at a standardised rate (1 mm/s) through the urethra, mapping the maximum urethral closure pressure (MUCP). An MUCP <20 cmH₂O in women indicates intrinsic sphincter deficiency (ISD), guiding selection of bulking agents (Bulkamid polyacrylamide hydrogel, Contigen) or a fascial pubovaginal sling over a synthetic mid-urethral sling. Valsalva Leak Point Pressure (VLPP) measures the minimum intravesical pressure at which leakage occurs during Valsalva manoeuvre — VLPP <60 cmH₂O indicates ISD; VLPP 60–90 cmH₂O indicates urethral hypermobility.

5. ELECTROMYOGRAPHY (EMG) OF THE EXTERNAL URETHRAL SPHINCTER

Patch surface electrodes or fine-wire/needle electrodes record sphincter activity during filling and voiding. Normal coordinated voiding shows sphincter relaxation concurrent with detrusor contraction. Paradoxical increase in EMG activity during voiding (detrusor-sphincter dyssynergia, DSD) is a hallmark of suprasacral neurogenic bladder and, if untreated, leads to progressive upper tract damage. EMG is essential in all neurogenic bladder evaluations.

6. VIDEO-URODYNAMICS (VUDS)

Considered the most comprehensive single urodynamic investigation, VUDS combines fluoroscopic cystourethrography with simultaneous multichannel pressure-flow recording. Real-time X-ray visualisation identifies bladder neck position, urethral morphology, vesico-ureteric reflux (graded I–V per the international classification), urethral diverticula, and bladder trabeculation during filling and voiding. VUDS is the standard of care for:

• Neurogenic bladder (spinal cord injury, spina bifida)

• Post-radical prostatectomy incontinence before AUS implantation

• Failed previous anti-incontinence surgery

• Suspected urethral stricture or diverticulum

• Paediatric uro-neurological assessment

7. AMBULATORY URODYNAMIC MONITORING (AUM)

Portable solid-state microtip pressure transducers record Pves, Pabd, and Pdet over 4–6 hours during the patient's normal activities (walking, stair-climbing, normal fluid intake). AUM has a 25–38% higher detection rate for detrusor overactivity compared to conventional laboratory UDS, making it the preferred investigation when conventional UDS is normal but the clinical suspicion for overactive bladder remains high. Available at tertiary urology and urogynaecology centres in India (Apollo, Fortis, Manipal) and the UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital, American Hospital Dubai).

8. URODYNAMICS-GUIDED TREATMENT PLANNING

The UDS report directly informs the therapeutic pathway:

• Detrusor overactivity → Antimuscarinics (Solifenacin 5–10 mg OD, Oxybutynin ER, Darifenacin) or β3-agonists (Mirabegron 25–50 mg OD); refractory cases → Onabotulinumtoxin A (Botox) intravesical injection 100 U (OAB) or 200 U (neurogenic); sacral neuromodulation (Axonics/InterStim)

• Urodynamic stress incontinence + urethral hypermobility → Tension-free vaginal tape (TVT) or transobturator tape (TOT)

• ISD → Bulkamid injection or autologous fascial sling

• Bladder outlet obstruction → TURP, HoLEP, GreenLight PVP, or UroLift

• Neurogenic DSD + low compliance → Clean intermittent catheterisation (CIC) ± anticholinergics; refractory → augmentation ileocystoplasty or urinary diversion

PHASE 1 — PRE-ARRIVAL PREPARATION (2–4 weeks before travel)

• Step 1: GAF Healthcare coordinates remote teleconsultation with the designated urologist or urogynaecologist. Patient shares bladder diary, ICIQ-UI SF questionnaire, recent urinalysis, PVR ultrasound report, and any prior UDS reports.

• Step 2: Clinical team confirms the specific UDS protocol required (simple uroflowmetry + cystometry vs. full video-urodynamics vs. AUM) and pre-authorises antibiotic prophylaxis (typically Nitrofurantoin 100 mg MR OD × 3 days pre-procedure, or as per local sensitivities).

• Step 3: GAF Healthcare submits e-Medical Visa application for India (processed in 1–5 business days) or confirms UAE entry requirements for the patient's nationality.

• Step 4: Urine culture result must be 'no growth' before travel confirmation. If positive, patient is treated locally with a targeted antibiotic and rescreened.

PHASE 2 — ARRIVAL AND DAY-BEFORE ASSESSMENT

• Step 5: Airport transfer to partner hotel or hospital-affiliated guest house. Dedicated GAF Healthcare patient coordinator meets the patient.

• Step 6: Day 1 — Outpatient clinic attendance: clinical history review, physical examination (pelvic examination in women including POP-Q staging, digital rectal examination in men), review of bladder diary, and repeat in-clinic uroflowmetry + PVR as baseline. Blood drawn for FBC, renal function, and CRP.

• Step 7: Written informed consent obtained. Procedure date confirmed (typically the following morning).

PHASE 3 — THE URODYNAMIC STUDY (Day 2, Outpatient/Day Case)

• Step 8: Patient arrives fasted from midnight only if sedation or concurrent cystoscopy is planned (most UDS require no fasting — patient should attend with a comfortably full bladder for initial free flow).

• Step 9: Free uroflowmetry and PVR measured on arrival.

• Step 10: Patient positioned in modified lithotomy or supine. Perineal skin cleansed with antiseptic. Under aseptic technique, a 6 Fr urodynamic catheter is inserted transurethrally into the bladder (dual lumen: one for filling, one for pressure measurement). A 6 Fr rectal pressure line with a finger cot balloon is positioned in the rectum or vagina.

• Step 11: Filling cystometry performed at 50 mL/min. ICS-standardised annotations logged: FSF, FDV, SDV, cystometric capacity, any detrusor overactivity, and leakage episodes. Provocative manoeuvres performed at capacity.

• Step 12: VLPP measured if stress incontinence is suspected. UPP trace performed if ISD is being assessed.

• Step 13: Pressure-flow voiding study: patient permitted to void with catheters in situ; simultaneous Pdet, Pves, and flow recorded.

• Step 14 (if scheduled): EMG patch electrodes applied to perineum; sphincter activity recorded throughout filling and voiding.

• Step 14a (video-urodynamics): Fluoroscopy unit positioned; filling medium changed to dilute iodinated contrast (typically 30% Omnipaque/Iohexol). Fluoroscopic images captured at FSF, FDV, capacity, and during voiding, with still images archived.

• Step 15: Catheters removed. Patient passes urine normally; post-procedure PVR confirmed on portable scanner. Total procedure time: 30–60 minutes (simple), 60–90 minutes (video-urodynamics).

PHASE 4 — IMMEDIATE POST-PROCEDURE (Hours 0–24)

• Step 16: Patient monitored for 30–60 minutes in the recovery bay. Instructed to maintain high oral fluid intake (≥2 litres over 4 hours) to flush the bladder and reduce infection risk.

• Step 17: Mild perineal discomfort and transient haematuria (pink-tinged urine) are expected for up to 24 hours and are managed with paracetamol 1 g QDS and increased hydration.

• Step 18: A single post-procedure dose of an appropriate antibiotic is administered (e.g., Trimethoprim 200 mg PO or Fosfomycin 3 g sachet) per local protocol.

• Step 19: If urine becomes frankly bloody, patient develops fever >38°C, or is unable to void, the patient contacts the 24-hour GAF Healthcare helpline for urgent review.

PHASE 5 — RESULTS CONSULTATION AND DEPARTURE PLANNING (Day 2–3)

• Step 20: The urodynamicist performs formal trace analysis using ICS-compliant software (SolarGold, MMS, Laborie Medical). A comprehensive UDS report—including annotated cystometrogram, flow curves, BOOI/BCI indices, DSD assessment, and VUDS imaging—is prepared within 24 hours.

• Step 21: Results consultation with the treating urologist. A personalised treatment roadmap is provided in a written letter (available in the patient's language via GAF's translation service), with specific recommendations: conservative measures, pharmacotherapy regimen, or a defined surgical plan.

• Step 22: If the patient elects to undergo treatment (e.g., Botox injection, sling surgery) at the same centre, a surgical admission date is scheduled and a new patient journey timeline begins. If the patient returns home for treatment, all records are digitised and shared via a secure cloud link.

• Step 23: Fit-to-fly assessment: In the absence of UTI, ongoing haematuria, or unresolved acute urinary retention, the patient is typically cleared for long-haul international flight within 24–72 hours of the study.